Monitoring IL-32 as a novel biomarker may help identify the immunotherapy that individuals would respond best to, while also ensuring those at greatest risk of developing T1D are more closely monitored or offered disease-modifying therapy. The gene discussed is IL32; the disease is type 1 diabetes mellitus.